Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Corporate Update (December 2025)
31 slides from Jasper Therapeutics's corporate update, Dec 2, 2025
Slide 1: Jasper Therapeutics ETESIAN Data + BEACON Investigation Update December 2025
Jasper Therapeutics ETESIAN Data + BEACON Investigation Update December 2025
Slide 2: Safe Harbor Statements
2 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statem ents. All statements other than stateme
Slide 3: Agenda
3 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION BEACON Trial Investigation Results • Ronald Martell, CEO Jasper Therapeutics • Dr. Daniel Adelman, Acting CMO Jasper Therapeutics BEACON Redosing Data & KOL Feedback • Dr. Martin Metz, Professor of Dermatology and Allergy,
Slide 4: BEACON Study Cohort and Initial Results
4 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION BEACON Study Cohort 8 and Cohort 9 Initial Results Anomalous efficacy observations led to internal investigation being undertaken July 2025 BEACON data for cohort 8 (240mg Q8W) and cohort 9 (240mg 180mg Q8W) showed an u
Slide 5: BEACON Trial Internal Investigation Results
BEACON Trial Internal Investigation Results Dr. Daniel Adelman, Acting CMO Jasper Therapeutics
Slide 6: Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria
6 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Screening/Eligibility • CSU diagnosis ≥ 6 mos. • UAS7 ≥ 16 • 18+ years • H1 - antihistamine - failed Study Operations • US Lead: Tom Casale, MD • EU Lead: Martin Metz, MD • ~30 sites in the US & EU Key Assessments • Diseas
Slide 7: Pharmacokinetics and Effect on Tryptase Consistent Across Cohorts 6, 8 and 9
7 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Pharmacokinetics and Effect on Tryptase Consistent Across Cohorts 6, 8 and 9 No indication of any variation in results due to initial DP lot used in Cohort 8 and Cohort 9 (mean SD) DAY Cohort 6 - 240mg Single Dose (n=6)
Slide 8: Briquilimab PK and PD Consistent Between UAS7 Responders and Non-Responders
8 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Data is shown as mean SD Placebo subjects are excluded Tryptase LLOQ is set as 0.8 ng/mL Briquilimab PK and PD are Consistent B etween UAS7 Responders and Non - Responders (Cohorts 6 - 9) Suggest that the investigational
Slide 9: Physical-Chemical and In-Vitro Experiments Show No Difference in Lots or Samples
9 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Physical - Chemical and In - Vitro Cell Line Experiments Show No Difference in Briquilimab Lots or Clinical Samples (internal and external labs) Non - Reduced CGE (% Monomer) SEC (% Main) Sample ID 95.2 96.1 Sample # 1 94.
Slide 10: Clinical Operations, Data Management and Site Investigations
10 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Clinical Operations, Data Management and Site Investigations No deviations in drug management, clinical conduct or data entry/handling noted • On - site investigations • Drug substance and drug product manufacturing • Dru
Slide 11: BEACON Trial Investigation KOL Review & Redosing Data
BEACON Trial Investigation KOL Review & Redosing Data Dr. Martin Metz, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin
Slide 12: Updated Clinical Data for Cohorts 8 & 9 Through 24 Weeks
12 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION As part of the internal investigation, patients in BEACON cohort 8 & 9 patients were switched to new DP lot through the end of their 24 - week dosing period • Lot A34954 immediately replaced at all clinical sites with A34
Slide 13: Cohorts 8 & 9 – Serum Tryptase
13 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 0 25 50 75 100 125 150 175 Cohort 8 & 9 Cohorts 8 & 9 – Serum Tryptase Deep reductions in tryptase levels maintained after transition to different DP lot 7 of 10 US Patients sw
Slide 14: No Incremental Efficacy Observed On New DP Lot in 8 of 9 Patients Redosed
14 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION No Incremental Efficacy Observed On New DP Lot in 8 of 9 Patients Redosed All patients received 240mg first dose, 7 of 10 Cohort 8 & 9 US patients switched to different lot by wk16 0 5 10 15 20 25 30 35 40 1 2 3 4 5 6 7 8
Slide 15: Cohort 9: Single Late Responder Achieved WC Disease After 3rd Dose
15 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Cohort 9: Single Late Responder Achieved WC Disease After 3 rd dose 20 - point reduction in UAS7 achieved with initial DP Lot 0 5 10 15 20 25 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 2
Slide 16: Briquilimab Was Well Tolerated and Demonstrated a Favorable Safety Profile
CONFIDENTIAL BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab Was Well Tolerated and Demonstrated a Favorable Safety Profile Pooled Placebo (N=19) n (%) Total Pooled Briquilimab (N=58) 5 n (%) 240mg D1 180mg Q8W Briquilimab (N=7) n (%) 240mg Q8W Briquilimab (N=
Slide 17: Safety Observations Possibly Related to KIT Blockade Were Generally Low Grade
17 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safety/Tolerability O bservations P ossibly R elated to KIT Blockade W ere G enerally L imited to Low G rade E vents Majority resolved during repeat dosing and none resulted in discontinuations Pooled Placebo (N=19) n (%)
Slide 18: Investigation Conclusions
18 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Investigation Conclusions Anomalous efficacy does not appear to be the result of any issue with the DP or study conduct • No issues or deviations noted in the testing done on DS and DP throughout the supply chain • Redosi
Slide 19: Briquilimab in Allergic Asthma
Briquilimab in Allergic Asthma Dr. Daniel Adelman, Acting CMO Jasper Therapeutics
Slide 20: Briquilimab Phase 1b/2a ETESIAN Study in Allergic Asthma
20 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Allergen Challenge & Methacholine PD20 Measured at 6 weeks and 12 weeks Briquilimab Phase 1b/2a ETESIAN Study in Allergic A sthma Double - blind, placebo - controlled, single dose, challenge study n=17 (1:1) 180 mg (Singl
Slide 21: Single 180mg Briquilimab Dose Drives Serum Tryptase Reductions at 6 Weeks
21 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Single 180mg Briquilimab Dose Drives Serum Tryptase Reductions at 6 Weeks PK/PD effect consistent with 180mg briquilimab activity observed in other studies
Slide 22: Briquilimab Mitigates the Effects of Allergen Challenge on FEV1 Response
22 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab M itigates the Effects of Allergen Challenge on FEV 1 Response Robust and sustained impact of mast - cell depletion on asthmatic response at 6 and 12 weeks EAR LAR EAR LAR
Slide 23: Patient Examples - SD 180mg Briquilimab Dose
23 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Patient Examples - SD 180mg Briquilimab Dose Substantial improvements in EAR & LAR observed in multiple patients
Slide 24: Briquilimab Dramatically Reduced Airway Hyper-Responsiveness
24 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab Dramatically Reduced Airway Hyper - Responsiveness Increased concentration of methacholine needed to drive 20% drop in FEV1 (PD20) 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 Screening Challenge 1 Challenge 2 Methac
Slide 25: Sputum Eosinophil Response Suppressed by Briquilimab
25 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Sputum Eosinophil Response Suppressed by Briquilimab Substantial eosinophil reduction at both 6 - week and 12 - week allergen challenge timepoints Pre - dose Allergen Challenge Allergen Challenge #1 Allergen Challenge #2
Slide 26: Preliminary Data Shows Briquilimab Was Well Tolerated in the ETESIAN Study
26 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Preliminary Data Shows Briquilimab Was Well Tolerated with a Favorable Safety Profile in the ETESIAN Study Placebo (N=8) n (%) Briquilimab 180mg Single Dose (N=9) n (%) Number of Participants With 3 (37.5) 5 (55.6) Any TE
Slide 27: Safety Observations Possibly Related to KIT Blockade Limited to Grade 1 Events
27 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Placebo (N=8) n (%) Total Pooled Briquilimab (N=9) n (%) Adverse Event as reported term 0 (0) 0 (0) Hair color changes 0 (0) 0 (0) Skin discoloration 0 (0) 1 (11.1) 1 Taste change/Hypogeusia 0 (0) 1 (11.1) 2 Neutrophil co
Slide 28: ETESIAN Study Summary
28 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION ETESIAN Study Summary First time a potent KIT - specific therapeutic targeting mast cells has demonstrated potential for the treatment of asthma PK/PD demonstrated deep & sustained biologic activity in key biomarkers, inc
Slide 29: BEACON Trial Next Steps
pis oe BEACON TRIAL Next Steps Ron Martell, CEO
Slide 30: Program Status and Next Steps
30 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Program Status and Next Steps Briquilimab development in mast - cell driven diseases continues to advance in multiple indications CSU - Briquilimab continues to demonstrate rapid onset, deep clinical response and favorabl
Slide 31: Jasper Therapeutics December 2025
Jasper Therapeutics NASDAQ: JSPR December 2025
Jasper Therapeutics — Corporate Update (December 2025) on 6ix